TearLab Corporation (TEAR) Posts Earnings Results, Beats Estimates By $0.06 EPS

TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) posted its quarterly earnings data on Monday. The medical research company reported ($0.67) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.06, Bloomberg Earnings reports.

TearLab Corporation (NASDAQ TEAR) traded up $0.11 during mid-day trading on Tuesday, hitting $0.84. The stock had a trading volume of 190,901 shares, compared to its average volume of 245,077. TearLab Corporation has a 12-month low of $0.59 and a 12-month high of $7.50. The company has a debt-to-equity ratio of -2.03, a quick ratio of 2.14 and a current ratio of 2.60.

TRADEMARK VIOLATION WARNING: This article was first reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.thestockobserver.com/2017/11/14/tearlab-corporation-tear-posts-earnings-results-beats-estimates-by-0-06-eps.html.

A number of research analysts have recently weighed in on TEAR shares. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of TearLab Corporation in a research report on Tuesday, August 15th. Zacks Investment Research raised TearLab Corporation from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research report on Thursday, August 31st. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $4.90.

About TearLab Corporation

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Earnings History for TearLab Corporation (NASDAQ:TEAR)

Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply